Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 4/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28837017 | 1.00 | GPR119 (0.46) | GPR119MEN1KMT2AMMP13ADAM17 | |
| SCHEMBL23364148 | 0.88 | CYP2D6 (0.37) | — | |
| SCHEMBL23364149 | 0.88 | CYP2D6 (0.37) | — | |
| SCHEMBL29784986 | 0.82 | STS (0.46) | GPR119 | |
| SCHEMBL29770088 | 0.82 | HTR7 (0.52) | GPR119MEN1KMT2A | |
| SCHEMBL28537559 | 0.82 | GPR119 (0.46) | GPR119MEN1KMT2AMMP13TP53 | |
| SCHEMBL28537628 | 0.82 | GPR119 (0.46) | GPR119MEN1KMT2AMMP13TP53 | |
| SCHEMBL28537557 | 0.82 | GPR119 (0.46) | GPR119MEN1KMT2AMMP13TP53 | |
| SCHEMBL30451018 | 0.81 | GPR119 (0.68) | GPR119MEN1KMT2AMMP13 | |
| SCHEMBL25547276 | 0.81 | GPR119 (0.68) | GPR119MEN1KMT2AMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-05 | — | — | US | disclosed |
| EP-4058455-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115003675-A | Novel functionalized lactams as 5-hydroxytryptamine receptor 7 modulators and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2022-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR1A, HTR2C | GPR119 234/4885MEN1 1891/4885KMT2A 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.